logo
ProjectEnded

Big Data EEG-Analysis for Advanced Personalised Medicine in Depression

Sector: Hospital • Location: Israel

Source: EU Funding & Tenders Portal

Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable t

Status
Closed
Sector
Hospital
Location
Israel
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about Big Data EEG-Analysis for Advanced Personalised Medicine in Depression

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Big Data EEG-Analysis for Advanced Personalised Medicine in Depression” is an infrastructure initiative in the Hospital sector, located in Israel. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable to accurately measure and compare how a brain functions hinders doctors’ ability to diagnose and treat suspected ailments. It also slows the substantiation of new therapies. And, just as importantly, it prevents each of us from truly understanding and taking ownership of the health of our body’s most important organ. Major Depressive Disorder (MDD) has been identified as the leading and most costly mental disorder, accounting for 33% of the total cost of brain disorders, and equal to 1% of the GDP. Each year, about 7% of the population suffer from MDD in Europe, equivalent to 52.98 million people. The current methods of treatment are prescribed through trial and error with patients rarely receiving the ‘right’ treatment from day one. This reduces response rates and delays remission, which has a heavy impact on the individual’s quality of life. elminda has developed the “PREDICT” tool which predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms for MDD patients. PREDICT determines personalised treatments for MDD patients based on validated electroencephalogram and event-related potential brain-related biomarkers. The tool predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms. This improves response rates, quality of life and results in significant savings for the healthcare systems.

Location

Country

Israel

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Hospital

Article published date

2026-02-01

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project